. 2025 Apr 24;104(7):105190. doi: 10.1016/j.psj.2025.105190

Table 3.

Average bacterial recovery (Log10 CFU/g) from fluff samples collected at DOH.

Trial	Treatment¹	Gram-negative bacteria			Bacillus spp.			Enterococcus spp.			Staphylococcus aureus
Trial 1	NC	0.00	±	0.00^c	3.96	±	0.14^c	2.47	±	1.23^b	0.00	±	0.00^c
	PM	5.75	±	0.12^a	6.52	±	0.11^b	4.93	±	0.14^a	5.04	±	0.07^b
	PM + F	2.47	±	1.23^b	3.80	±	0.10^c	0.00	±	0.00^c	0.00	±	0.00^c
	PM + MCR002	5.63	±	0.19^a	8.33	±	0.20^a	0.00	±	0.00^c	1.23	±	1.23^c
	PM + MCR009	0.00	±	0.00^c	8.37	±	0.33^a	0.00	±	0.00^c	4.11	±	0.06^b
	PM + Combo	6.10	±	0.10^a	8.90	±	0.10^a	0.00	±	0.00^c	6.85	±	0.15^a
Trial 2	NC	0.00	±	0.00^d	4.34	±	0.08^b	0.00	±	0.00^c	0.00	±	0.00^d
	PM	6.34	±	0.11^b	4.46	±	0.16^b	6.34	±	0.12^b	6.45	±	0.20^c
	PM + F	0.00	±	0.00^d	1.85	±	0.83^c	0.00	±	0.00^c	0.78	±	0.78^d
	PM + MCR002	5.51	±	0.07^c	9.31	±	0.19^a	0.00	±	0.00^c	6.95	±	0.11^bc
	PM + MCR009	6.48	±	0.38^b	8.65	±	0.17^a	6.36	±	0.21^b	7.60	±	0.18^ab
	PM + Combo	8.00	±	0.31^a	9.68	±	0.24^a	7.65	±	0.09^a	8.20	±	0.25^a
Trial 3	NC	1.95	±	0.88^c	5.83	±	0.15^c	3.02	±	1.35^b	0.00	±	0.00^c
	PM	6.47	±	0.08^a	6.91	±	0.13^b	6.21	±	0.07^a	4.39	±	0.14^a
	PM + F	5.33	±	0.40^ab	5.90	±	0.15^c	2.68	±	1.20^b	0.00	±	0.00^c
	PM + MCR002	4.40	±	0.26^b	8.28	±	0.08^a	0.00	±	0.00^c	4.02	±	1.07^ab
	PM + MCR009	6.12	±	0.08^a	8.29	±	0.12^a	0.00	±	0.00^c	2.68	±	0.85^b

Data expressed as mean Log10 CFU/g ± SE.

^{a, b, c, d} Differing superscripts indicate significant (P < 0.05) differences between treatments by trial and type of bacteria. Trials 1-3 n = 12 treatment/bacteria. Trial 1 n = 3 plates/treatment/bacteria. Trials 2 and 3 n = 6 plates/treatment/bacteria.

Treatment abbreviations: Negative Control (NC); Pathogen Mix (PM); PM + Formaldehyde (PM + F); PM + B. amyloliquefaciens MCR002 (PM + MCR002); PM + B. amyloliquefaciens MCR009 (PM + MCR009); PM + MCR002 + MCR009 (PM + Combo).